Summary
A strategy of intravenous abciximab (a glycoprotein [GP] IIb/IIIa inhibitor) plus unfractionated heparin, compared with bivalirudin, an IV direct thrombin inhibitor, failed to improve clinical outcomes and increased the risk of bleeding in patients with acute non-ST-segment elevation myocardial infarction (NSTEMI) who were undergoing percutaneous coronary intervention, according to results of the ISAR-REACT 4 trial [NCT00373451].
- Cardiology Clinical Trials
- Interventional Techniques & Devices
- Myocardial Infarction
- © 2011 MD Conference Express®
Tools
ISAR-REACT 4 – Bivalirudin Similar to Abciximab/Heparin in Reducing Ischemic Outcomes in NSTEMI and Has Significantly Less Bleeding
Permalink:
Table of contents
Cited By...
- No citing articles found.